NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment

Описание к видео NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment

Earn CME for related activities: https://hmpeducation.com/

This on-demand webcast examines the efficacy and safety, indications, and cost utility of available EGFR tyrosine kinase inhibitors (TKIs) and monoclonal antibodies into optimal first-line selection and NSCLC pathway placement strategies.

Комментарии

Информация по комментариям в разработке

Похожие видео